| The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients M Del Re, E Biasco, S Crucitta, L Derosa, E Rofi, C Orlandini, M Miccoli, ... European urology 71 (4), 680-687, 2017 | 270 | 2017 |
| PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC M Del Re, R Marconcini, G Pasquini, E Rofi, C Vivaldi, F Bloise, ... British journal of cancer 118 (6), 820-824, 2018 | 228 | 2018 |
| Concise review: chronic myeloid leukemia: stem cell niche and response to pharmacologic treatment E Arrigoni, M Del Re, S Galimberti, G Restante, E Rofi, S Crucitta, ... Stem cells translational medicine 7 (3), 305-314, 2018 | 90 | 2018 |
| Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients M Del Re, I Bertolini, S Crucitta, L Fontanelli, E Rofi, C De Angelis, ... Breast Cancer Research and Treatment 178, 57-62, 2019 | 78 | 2019 |
| Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy M Del Re, S Crucitta, G Gianfilippo, A Passaro, I Petrini, G Restante, ... International journal of molecular sciences 20 (16), 3951, 2019 | 78 | 2019 |
| The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate/prednisone and enzalutamide M Del Re, S Fogli, L Derosa, F Massari, P De Souza, S Crucitta, ... Cancer treatment reviews 55, 71-82, 2017 | 70 | 2017 |
| Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs S Fogli, C Porta, M Del Re, S Crucitta, G Gianfilippo, R Danesi, BI Rini, ... Cancer Treatment Reviews 84, 101966, 2020 | 55 | 2020 |
| Implications of KRAS mutations in acquired resistance to treatment in NSCLC M Del Re, E Rofi, G Restante, S Crucitta, E Arrigoni, S Fogli, M Di Maio, ... Oncotarget 9 (5), 6630, 2018 | 52 | 2018 |
| Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? M Del Re, V Citi, S Crucitta, E Rofi, F Belcari, R van Schaik, R Danesi Pharmacological Research 107, 398-406, 2016 | 51 | 2016 |
| From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC P Bordi, M Del Re, R Minari, E Rofi, S Buti, G Restante, A Squadrilli, ... Lung Cancer 131, 78-85, 2019 | 46 | 2019 |
| DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients M Del Re, S Cinieri, A Michelucci, S Salvadori, F Loupakis, M Schirripa, ... The pharmacogenomics journal 19 (6), 556-563, 2019 | 45 | 2019 |
| The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response M Del Re, P Bordi, E Rofi, G Restante, S Valleggi, R Minari, S Crucitta, ... British journal of cancer 119 (10), 1252-1258, 2018 | 41 | 2018 |
| Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients F Martignano, U Munagala, S Crucitta, A Mingrino, R Semeraro, M Del Re, ... Molecular cancer 20, 1-6, 2021 | 40 | 2021 |
| Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide M Del Re, V Conteduca, S Crucitta, G Gurioli, C Casadei, G Restante, ... Prostate cancer and prostatic diseases 24 (2), 524-531, 2021 | 40 | 2021 |
| Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients M Del Re, C Omarini, L Diodati, M Palleschi, I Meattini, S Crucitta, ... ESMO open 6 (5), 100231, 2021 | 38 | 2021 |
| Concise review: resistance to tyrosine kinase inhibitors in non-small cell lung cancer: the role of cancer stem cells M Del Re, E Arrigoni, G Restante, A Passaro, E Rofi, S Crucitta, ... Stem Cells 36 (5), 633-640, 2018 | 38 | 2018 |
| Incidence of T790M in patients with NSCLC progressed to gefitinib, erlotinib, and afatinib: a study on circulating cell-free DNA M Del Re, I Petrini, F Mazzoni, S Valleggi, G Gianfilippo, D Pozzessere, ... Clinical lung cancer 21 (3), 232-237, 2020 | 36 | 2020 |
| A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC M Del Re, F Cucchiara, E Rofi, L Fontanelli, I Petrini, N Gri, G Pasquini, ... Cancer Immunology, Immunotherapy 70, 1667-1678, 2021 | 34 | 2021 |
| PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients M Del Re, S Crucitta, G Lorenzini, C De Angelis, L Diodati, D Cavallero, ... Pharmacological Research 163, 105241, 2021 | 33 | 2021 |
| Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours S Crucitta, F Cucchiara, R Mathijssen, J Mateo, A Jager, A Joosse, ... Cancer treatment reviews 104, 102340, 2022 | 31 | 2022 |
Marzia Del Re, PharmD, PhDSenior Researcher @ Unit of Clinical Pharmacology and Pharmacogenetics, University of Pisa在 unipi.it 的电子邮件经过验证
Marzia Del Re, PharmD, PhDSenior Researcher @ Unit of Clinical Pharmacology and Pharmacogenetics, University of Pisa在 unipi.it 的电子邮件经过验证